Aktis Oncology (AKTS) holders convert preferred and buy common

Rhea-AI Filing Summary

Vida Ventures II, LLC and Vida Ventures II-A, LLC, both 10% owners of Aktis Oncology, Inc., reported multiple transactions dated 01/12/2026. Series A and Series B Redeemable Convertible Preferred Stock automatically converted into Common Stock on a 3.8044-for-1 basis immediately before the closing of Aktis Oncology’s initial public offering, with no additional consideration paid.

Following these conversions and open-market purchases, Vida Ventures II, LLC indirectly held 5,671,825 shares of Common Stock after acquiring 4,859,370 shares through conversion and buying 812,455 shares at $18 per share. Vida Ventures II-A, LLC indirectly held 157,387 shares of Common Stock after receiving 134,842 shares through conversion and purchasing 22,545 shares at $18 per share.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vida Ventures II, LLC

(Last) (First) (Middle)

C/O VIDA VENTURES ADVISORS, LLC

10100 SANTA MONICA BOULEVARD, SUITE 1500

(Street)

LOS ANGELES CA 90067

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/12/2026		C(1)		4,859,370	A	(1)	4,859,370	I	See Footnote(2)
Common Stock	01/12/2026		P		812,455	A	$18	5,671,825	I	See Footnote(2)
Common Stock	01/12/2026		C(1)		134,842	A	(1)	134,842	I	See Footnote(3)
Common Stock	01/12/2026		P		22,545	A	$18	157,387	I	See Footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Redeemable Convertible Preferred Stock	(4)	01/12/2026		C			14,838,250	(4)	(4)	Common Stock	3,900,284	$0	0	I	See Footnote(2)
Series A Redeemable Convertible Preferred Stock	(4)	01/12/2026		C			411,750	(4)	(4)	Common Stock	108,229	$0	0	I	See Footnote(3)
Series B Redeemable Convertible Preferred Stock	(5)	01/12/2026		C			3,648,750	(5)	(5)	Common Stock	959,086	$0	0	I	See Footnote(2)
Series B Redeemable Convertible Preferred Stock	(5)	01/12/2026		C			101,250	(5)	(5)	Common Stock	26,613	$0	0	I	See Footnote(3)

1. Name and Address of Reporting Person^*

Vida Ventures II, LLC

(Last) (First) (Middle)

C/O VIDA VENTURES ADVISORS, LLC

10100 SANTA MONICA BOULEVARD, SUITE 1500

(Street)

LOS ANGELES CA 90067

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

VIDA VENTURES II-A, LLC

(Last) (First) (Middle)

10100 SANTA MONICA BOULEVARD.,

SUITE 1500

(Street)

LOS ANGELES CA 90067

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Represents shares of the Issuer's Common Stock received upon conversion of shares of the Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock on a 3.8044-for-1 basis without payment of additional consideration.

2. These shares are held by Vida Ventures II, LLC ("VV II"). VV Manager II, LLC ("VVM II") is the manager of VV II and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and Helen Kim, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.

3. These shares are held by Vida Ventures II-A, LLC ("VV II-A"). VVM II is the manager of VV II-A and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II-A. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and Helen Kim, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II-A and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.

4. The Series A Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration.

5. The Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration.

	VIDA VENTURES II, LLC, By: VV Manager II, LLC, its Manager, By: /s/ Jean-Philippe Kouakou-Zebouah, Authorized Signatory	01/12/2026
	VIDA VENTURES II-A, LLC, By: VV Manager II, LLC, its Manager, By: /s/ Jean-Philippe Kouakou-Zebouah, Authorized Signatory	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Vida Ventures report in Aktis Oncology (AKTS)?

Vida Ventures II, LLC and Vida Ventures II-A, LLC reported automatic conversion of Aktis Oncology Series A and B Redeemable Convertible Preferred Stock into Common Stock and open-market purchases of additional Common Stock on 01/12/2026.

What was the conversion ratio for Aktis Oncology preferred stock in this Form 4?

The Series A and Series B Redeemable Convertible Preferred Stock automatically converted into Aktis Oncology Common Stock on a 3.8044-for-1 basis, without payment of additional consideration.

How many Aktis Oncology shares does Vida Ventures II, LLC hold after these transactions?

After the reported transactions, Vida Ventures II, LLC indirectly beneficially owned 5,671,825 shares of Aktis Oncology Common Stock.

How many Aktis Oncology shares does Vida Ventures II-A, LLC hold after these transactions?

Vida Ventures II-A, LLC indirectly beneficially owned 157,387 shares of Aktis Oncology Common Stock after the conversions and purchases.

At what price did the Vida Ventures entities buy additional Aktis Oncology common shares?

Both Vida Ventures II, LLC and Vida Ventures II-A, LLC reported open-market purchases of Aktis Oncology Common Stock at a price of $18 per share.

Are the Aktis Oncology shares held directly or indirectly by Vida Ventures?

The Aktis Oncology Common Stock reported in this Form 4 is held indirectly by Vida Ventures II, LLC and Vida Ventures II-A, LLC, with voting and investment power described through management entities in the footnotes.

How is this Form 4 related to Aktis Oncology’s initial public offering?

The filing notes that the Series A and Series B Redeemable Convertible Preferred Stock automatically converted into Common Stock immediately prior to the closing of Aktis Oncology’s initial public offering, at a 3.8044-for-1 rate.